Effects of B-GOS on cognitive behavior and depression of transgenic mice with Alzheimer's disease

doi:10.12047/j.cjap.6105.2021.028

Abstract

Abstract: Objective: To investigate the effects of novel BimunoGalactooligosaccharides (B-GOS) on cognitive behavior and depression of APP/PS1/tau Alzheimer's disease transgenic mice. Methods: Five-month-old male APP/PS1/tau AD transgenic mice and C57BL/6J control mice were divide into C57+Vehicle group, C57+B-GOS group, APP/PS1/tau+Vehicle group and APP/PS1/tau+B-GOS group, with 10 mice in each group. After continuous administration of B-GOS for 5 months, the cognitive behavior and depressive mood changes of mice in each group were detected by open field experiment, new object recognition experiment, Y maze experiment, Morris water maze experiment, tail suspension test, forced swimming test and conditioned fear experiment, respectively. Results: ①Open field experiment: the percentage of activity time in the central area of open field in APP/PS1/tau+Vehicle group mice was significantly lower than that in C57+Vehicle group mice (P＜0.01), and was remarkably increased after B-GOS intervention (P＜0.05). ② New object recognition experiment: the new object recognition index (NOI) of APP/PS1/tau+Vehicle group mice was significantly lower than that of C57+Vehicle group mice (P＜0.01), and was observably increased after B-GOS intervention (P＜0.05). ③ Y maze experiment: the spontaneous alternation correct rate of APP/PS1/tau+Vehicle group mice was notably lower than that in C57+Vehicle group (P＜0.01), and was distinctly increased after B-GOS intervention (P＜0.01). ④ Classical water maze experiment: the escape latency of APP/PS1/tau+Vehicle group mice on the 4th and 5th days was significantly longer than that of C57+Vehicle group mice (P＜0.01), which was markedly shortened after B-GOS intervention (P＜0.05). During the space exploration phase, the percentage of swimming time in the target quadrant and the times of crossing the platform in APP/PS1/tau+Vehicle group mice were significantly lower than those in C57+Vehicle group mice (P＜0.01), which were notably increased after B-GOS intervention (P＜0.01). ⑤ Tail suspension test and forced swimming test: the percentage of immobility time in APP/PS1/tau+Vehicle group mice was dramatically higher than that in C57+Vehicle group mice (P＜0.01), and was obviously reduced after B-GOS intervention (P＜ 0.01). ⑥ Conditioned fear experiment: before conditioned stimulus (CS), the freezing ratio of mice in each group had no statistical difference (P＞0.05). After CS, the freezing ratio of APP/PS1/tau+Vehicle group mice was significantly lower than that of C57+Vehicle group mice (P＜0.01), and was notably increased after B-GOS intervention (P＜0.01). Conclusion: B-GOS could reverse the cognitive behavioral impairment of APP/PS1/tau mice and alleviate their depression to a large extent.

Key words: Alzheimer&apos, s disease, Bimuno Galactooligosaccharides, Bifidobacterium, cognitive dysfunction, depression

CLC Number:

R338

YANG Dan, QIAO Jing, WANG Jia-xin, WEI Wu-yang, ZHAO Zi-xin, CAI Hong-yan. Effects of B-GOS on cognitive behavior and depression of transgenic mice with Alzheimer's disease[J]. CJAP, 2021, 37(3): 240-246.

References 22

[1]	Kotagale N, Deshmukh R, Dixit M, et al. Agmatine ameliorates manifestation of depression-like behavior and hippocampal neuroinflammation in mouse model of Alzheimer's disease[J]. Brain Res Bull, 2020, 160: 56-64.
[2]	Oddo S, Caccamo A, Shepherd JD, et al. Triple-trans-genic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction[J]. Neuron, 2003, 39 (3): 409-421.
[3]	Harach T, Marungruang N, Duthilleul N, et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota [J]. Sci Rep, 2017, 7: 41802.
[4]	Vogt NM, Kerby RL, Dill-McFarland KA, et al. Gut microbiome alterations in Alzheimer’s disease[J]. Sci Rep, 2017, 7(1): 13537.
[5]	Rezaei Asl Z, Sepehri G, Salami M. Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer's disease[J]. Behav Brain Res, 2019, 376: 112183.
[6]	马丽娜, 刘剑刚, 李浩. 肠道微生物与阿尔茨海默病的相关性研究进展[J]. 中国药理学通报, 2017, 33(7): 893-896.
[7]	Gibson GR, Probert HM, Loo JV, et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics[J]. Nutr Res Rev, 2004, 17(2): 259-275.
[8]	陈艳秋. 低聚半乳糖对 AD 模型小鼠认知功能的影响及机制探讨[D]. 辽宁: 中国医科大学, 2019.
[9]	Tzortzis G, Goulas AK, Gee JM, et al. A novel galactooligosaccharide mixture increases the bifidobacterial population numbers in a continuous in vitro fermentation system and in the proximal colonic contents of pigs in vivo[J]. J Nutr, 2005, 135(7): 1726-1731.
[10]	Gronier B, Savignac HM, Di Miceli Met, et al. Increased cortical neuronal responses to NMDA and improved attentional set-shifting performance in rats following prebiotic (B-GOS) ingestion[J].Eur Neuropsychopharmacol, 2018, 28(1): 211-224.
[11]	Schmidt K, Cowen PJ, Harmer CJ, et al. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers[J]. Psychopharmacology, 2015, 232(10): 1793-1801.
[12]	Yang XD, Wang LK, Wu HY, et al. Effects of prebiotic galacto-oligosaccharide on postoperative cognitive dysfunction and neuroinflammation through targeting of the gut-brain axis[J]. BMC Anesthesiol, 2018, 18(1): 177.
[13]	Wu M, Shi H, He Y, et al. Colivelin ameliorates impairments in cognitive behaviors and synaptic plasticity in APP/PS1 transgenic mice[J]. J Alzheimers Dis, 2017, 59(3): 1067-1078.
[14]	Li T, Jiao JJ, Hlscher C, et al. A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease[J]. Hippocampus, 2018, 28(5): 358-372.
[15]	Wang ZJ, Han YF, Zhao F, et al. A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice[J]. Horm Behav, 2020, 118: 104640.
[16]	胡梦明, 闫旭东, 张秀敏, 等. 无线神经遥测技术在阿尔茨海默病转基因小鼠恐惧学习记忆活动中的应用——海马Theta节律观察[J]. 生理学报, 2018, 70(5): 571-578.
[17]	Tzortzis G, Goulas AK, Gibson GR. Synthesis of prebiotic galactooligosaccharides using whole cells of a novel strain, Bifidobacterium bifidum NCIMB 41171[J]. Appl Microbiol Biotechnol, 2005, 68(3): 412-416.
[18]	Shoaf K, Mulvey GL, Armstrong GD, et al. Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells[J]. Infect Immun, 2006, 74(12): 6920-6928.
[19]	Vulevic J, Drakoularakou A, Yaqoob P, et al. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers[J]. Am J Clin Nutr, 2008, 88(5): 1438-1446.
[20]	Vulevic J, Juric A, Tzortzis G, et al. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults[J]. J Nutr, 2013, 143(3): 324-331.
[21]	Hebert JC, Radford-Smith DE, Probert F, et al. Mom's diet matters: Maternal prebiotic intake in mice reduces anxiety and alters brain gene expression and the fecal microbiome in offspring[J]. Brain Behav Immun, 2021, 91: 230-244.
[22]	Savignac HM, Couch Y, Stratford M, et al. Prebiotic administration normalizes lipopolysaccharide (LPS)-induced anxiety and cortical 5-HT2A receptor and IL1-β levels in male mice[J]. Brain Behav Immun, 2016, 52: 120-131.